InflaRx (IFRX) News Today $2.08 +0.02 (+0.97%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period InflaRx initiated with a Buy at Lucid CapitalNovember 20 at 12:49 PM | markets.businessinsider.comIs InflaRx N.V. (IFRX) the Best German Stock to Buy Now?November 20 at 12:49 PM | msn.comFY2024 Earnings Estimate for InflaRx Issued By HC WainwrightNovember 16, 2024 | americanbankingnews.comInflaRx Shares Rise 12% After Regulators Favor Authorization of GohibicNovember 16, 2024 | marketwatch.comInflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatmentNovember 16, 2024 | msn.comInflaRx receives positive CHMP opinion for GOHIBIC for SARS-CoV-2-induced ARDSNovember 16, 2024 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on InflaRx (IFRX)November 16, 2024 | markets.businessinsider.comInflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress SyndromeNovember 15, 2024 | globenewswire.comFY2024 EPS Estimates for InflaRx Decreased by HC WainwrightInflaRx (NASDAQ:IFRX - Free Report) - Research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of InflaRx in a report issued on Monday, November 11th. HC Wainwright analyst E. White now expects that the company will post earnings of ($1.05) per shareNovember 14, 2024 | marketbeat.comFY2024 EPS Estimates for InflaRx Cut by Leerink PartnrsInflaRx (NASDAQ:IFRX - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for InflaRx in a research note issued to investors on Monday, November 11th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($1.02) pNovember 14, 2024 | marketbeat.comInflaRx’s Strategic Advancements and Robust Financial Health Support Buy RatingNovember 13, 2024 | markets.businessinsider.comLifeSci Capital Keeps Their Hold Rating on InflaRx (IFRX)November 13, 2024 | markets.businessinsider.comInflaRx’s Promising Market Potential and Financial Stability Justify Buy RatingNovember 12, 2024 | markets.businessinsider.comInflaRx Reports Q3 2024 Financial Results and ProgressNovember 11, 2024 | tipranks.comInflaRx (NASDAQ:IFRX) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a report on Monday.November 11, 2024 | marketbeat.comInflaRx Reports Rising Revenue Amidst Significant LossesNovember 9, 2024 | markets.businessinsider.comInflaRx expects cash to fund operations into 2026November 9, 2024 | finance.yahoo.comInflaRx Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 8, 2024 | globenewswire.comEarnings Preview: InflaRxNovember 7, 2024 | benzinga.comInflaRx (IFRX) Set to Announce Earnings on FridayInflaRx (NASDAQ:IFRX) will be releasing earnings before the market opens on Friday, November 8, Zacks reports.November 1, 2024 | marketbeat.comInflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation ConferenceOctober 31, 2024 | finance.yahoo.comInflaRx (NASDAQ:IFRX) Sees Significant Growth in Short InterestInflaRx (NASDAQ:IFRX - Get Free Report) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 262,900 shares, an increase of 63.2% from the September 15th total of 161,100 shares. Based on an average daily volume of 59,400 shares, the short-interest ratio is presently 4.4 days.October 14, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBuy Rating on InflaRx as Gohibic Shows Promise and Financials StrengthenSeptember 26, 2024 | markets.businessinsider.comInflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology CongressSeptember 25, 2024 | globenewswire.com3 Penny Stocks To Buy With Just $750September 24, 2024 | 247wallst.comInflaRx (NASDAQ:IFRX) Shares Up 1.3%InflaRx (NASDAQ:IFRX) Trading 1.3% HigherSeptember 4, 2024 | marketbeat.comInflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human DiseasesSeptember 3, 2024 | globenewswire.comInflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in AugustInflaRx (NASDAQ:IFRX - Get Free Report) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 227,600 shares, a decrease of 9.2% from the July 31st total of 250,600 shares. Based on an average trading volume of 99,000 shares, the days-to-cover ratio is presently 2.3 days.September 1, 2024 | marketbeat.comInflaRx Announces Participation in September Investor EventsAugust 27, 2024 | globenewswire.comIFRX Sep 2024 2.500 call (IFRX240920C00002500)August 18, 2024 | finance.yahoo.comInflaRx Buy Rating Backed by Promising Drug Prospects and Financial StabilityAugust 13, 2024 | markets.businessinsider.comShort Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4%InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totalling 250,600 shares, a growth of 281.4% from the July 15th total of 65,700 shares. Based on an average daily volume of 128,800 shares, the short-interest ratio is currently 1.9 days.August 13, 2024 | marketbeat.comInflaRx N.V.: InflaRx Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | finanznachrichten.deInflaRx Buy Rating Affirmed: Financial Stability and Gohibic’s Market PotentialAugust 8, 2024 | markets.businessinsider.comIFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q2 2024August 8, 2024 | markets.businessinsider.comInflaRx Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | globenewswire.comInflaRx Q2 2024 Earnings PreviewAugust 7, 2024 | msn.comInflaRx to Report Second Quarter 2024 Results on August 8, 2024August 1, 2024 | globenewswire.comInflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human DiseasesJuly 30, 2024 | finance.yahoo.comShort Interest in InflaRx (NASDAQ:IFRX) Rises By 151.1%InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 232,800 shares, a growth of 151.1% from the June 15th total of 92,700 shares. Based on an average trading volume of 177,000 shares, the days-to-cover ratio is currently 1.3 days.July 12, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Short Interest UpdateInflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 92,700 shares, an increase of 233.5% from the May 31st total of 27,800 shares. Based on an average daily trading volume, of 194,800 shares, the days-to-cover ratio is currently 0.5 days.June 27, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of InflaRx in a research report on Monday.June 24, 2024 | marketbeat.comInflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)June 24, 2024 | globenewswire.comInflaRx Hosts R&D Event Highlighting the Promise of INF904June 5, 2024 | globenewswire.comInflaRx (NASDAQ:IFRX) Trading Up 10.5%InflaRx (NASDAQ:IFRX) Trading Up 10.5%June 4, 2024 | marketbeat.comInflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsMay 21, 2024 | finance.yahoo.comInflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsMay 21, 2024 | globenewswire.comInflaRx’s Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D InsightsMay 10, 2024 | markets.businessinsider.comInflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG TreatmentMay 9, 2024 | markets.businessinsider.com Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.130.49▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼91▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Terns Pharmaceuticals News Today Korro Bio News Today MeiraGTx News Today Arcturus Therapeutics News Today REGENXBIO News Today Xeris Biopharma News Today Y-mAbs Therapeutics News Today Aura Biosciences News Today SIGA Technologies News Today Taysha Gene Therapies News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IFRX Stock Alerts